Abstract

To fight the Covid-19 pandemic caused by the RNA virus SARS-CoV-2 a global vaccination campaign is in progress to achieve the immunization of billions of people mainly with adenoviral vector- or mRNA-based vaccines, all of which encode the SARS-CoV-2 Spike protein. In some rare cases, cerebral venous sinus thromboses (CVST) have been reported as a severe side effect occurring 4 to 14 days after the first vaccination and were often accompanied by thrombocytopenia. Besides CVST, splanchnic vein thromboses (SVT) and other thromboembolic events have been observed. These events only occurred following vaccination with adenoviral vector-based vaccines but not following vaccination with mRNA-based vaccines. Meanwhile, scientists have proposed an immune-based pathomechanism and the condition has been coined Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). Here, we describe an unexpected mechanism that could explain thromboembolic events occurring with DNA-based but not with RNA-based vaccines. We show that DNA-encoded mRNA coding for Spike protein can be spliced in a way that the transmembrane anchor of Spike is lost, so that nearly full-length Spike is secreted from cells. Secreted Spike variants could potentially initiate severe side effects when binding to cells via the ACE2 receptor. Avoiding such splicing events should become part of a rational vaccine design to increase safety of prospective vaccines.

Data availability

The original WUHAN SARS-CoV-2 sequence is available in the NCBI database (NCBI Reference Sequence: NC_045512.2); the adenoviral and codon-optimized Spike sequence data have a protected intellectual property by the companies. The primary sequence of Ad5.S, designed and used by the colleagues in Ulm, can be retrieved upon request (contact Prof. Stefan Kochanek).

The following previously published data sets were used

Article and author information

Author details

  1. Eric Kowarz

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Lea Krutzke

    Department of Gene Therapy, University of Ulm, Ulm, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4092-4131
  3. Marius Külp

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Patrick Streb

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Patrizia Larghero

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Jennifer Reis

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Silvia Bracharz

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Tatjana Engler

    Department of Gene Therapy, University of Ulm, Ulm, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Stefan Kochanek

    Department of Gene Therapy, University of Ulm, Ulm, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Rolf Marschalek

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    For correspondence
    Rolf.Marschalek@em.uni-frankfurt.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4870-3445

Funding

Goethe University Corona Task Force

  • Rolf Marschalek

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Kowarz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 10,818
    views
  • 781
    downloads
  • 46
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Eric Kowarz
  2. Lea Krutzke
  3. Marius Külp
  4. Patrick Streb
  5. Patrizia Larghero
  6. Jennifer Reis
  7. Silvia Bracharz
  8. Tatjana Engler
  9. Stefan Kochanek
  10. Rolf Marschalek
(2022)
Vaccine-induced COVID-19 mimicry syndrome
eLife 11:e74974.
https://doi.org/10.7554/eLife.74974

Share this article

https://doi.org/10.7554/eLife.74974

Further reading

    1. Cell Biology
    Chun-Wei Chen, Jeffery B Chavez ... Bruce J Nicholson
    Research Article

    Endometriosis is a debilitating disease affecting 190 million women worldwide and the greatest single contributor to infertility. The most broadly accepted etiology is that uterine endometrial cells retrogradely enter the peritoneum during menses, implant and form invasive lesions in a process analogous to cancer metastasis. However, over 90% of women suffer retrograde menstruation, but only 10% develop endometriosis, and debate continues as to whether the underlying defect is endometrial or peritoneal. Processes implicated in invasion include: enhanced motility; adhesion to, and formation of gap junctions with, the target tissue. Endometrial stromal (ESCs) from 22 endometriosis patients at different disease stages show much greater invasiveness across mesothelial (or endothelial) monolayers than ESCs from 22 control subjects, which is further enhanced by the presence of EECs. This is due to enhanced responsiveness of endometriosis ESCs to the mesothelium, which induces migration and gap junction coupling. ESC-PMC gap junction coupling is shown to be required for invasion, while coupling between PMCs enhances mesothelial barrier breakdown.

    1. Cell Biology
    Satoshi Ninagawa, Masaki Matsuo ... Kazutoshi Mori
    Research Advance

    How the fate (folding versus degradation) of glycoproteins is determined in the endoplasmic reticulum (ER) is an intriguing question. Monoglucosylated glycoproteins are recognized by lectin chaperones to facilitate their folding, whereas glycoproteins exposing well-trimmed mannoses are subjected to glycoprotein ER-associated degradation (gpERAD); we have elucidated how mannoses are sequentially trimmed by EDEM family members (George et al., 2020; 2021 eLife). Although reglucosylation by UGGT was previously reported to have no effect on substrate degradation, here we directly tested this notion using cells with genetically disrupted UGGT1/2. Strikingly, the results showed that UGGT1 delayed the degradation of misfolded substrates and unstable glycoproteins including ATF6α. An experiment with a point mutant of UGGT1 indicated that the glucosylation activity of UGGT1 was required for the inhibition of early glycoprotein degradation. These and overexpression-based competition experiments suggested that the fate of glycoproteins is determined by a tug-of-war between structure formation by UGGT1 and degradation by EDEMs. We further demonstrated the physiological importance of UGGT1, since ATF6α cannot function properly without UGGT1. Thus, our work strongly suggests that UGGT1 is a central factor in ER protein quality control via the regulation of both glycoprotein folding and degradation.